Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cresco LabsFRA:6CQ -3.87%41 Debt-to-Equity is 1.65 as of Jun. 2026, which is 83% above its 10-year median of 0.90. GuruFocus rates FRA:6CQ with a GF Score™ of 41/100 and a GF Value™ of €0.73 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 810 Drug Manufacturers companies, Cresco Labs ranks worse than 93.46% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cresco Labs's Debt-to-Equity or its related term are showing as below:
FRA:6CQ'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.88 Med: 0.9 Max: 1.75
Current: 1.65
During the past 13 years, the highest Debt-to-Equity Ratio of Cresco Labs was 1.75. The lowest was -0.88. And the median was 0.90.
FRA:6CQ's Debt-to-Equity is ranked worse than 93.46% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs FRA:6CQ: 1.65
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cresco Labs Debt-to-Equity Related Terms
Cresco Labs Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cresco Labs's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cresco Labs Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cresco Labs's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cresco Labs (FRA:6CQ) has a Debt-to-Equity of 1.65 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cresco Labs and its competitors. This is 83% above median its historical median of 0.90. According to the industry distribution chart, Cresco Labs ranks #757 out of 810 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Cresco Labs' Debt-to-Equity too high?
Cresco Labs' current Debt-to-Equity of 1.65 is 83% above median its 10-year median of 0.90. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Cresco Labs' value of 1.65 is 489.3% above this industry median. Based on the distribution chart, Cresco Labs ranks #757 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cresco Labs has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #757 out of 810 companies for Debt-to-Equity. This places Cresco Labs in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Cresco Labs' value of 1.65 is 489.3% above this benchmark. While the company's 10-year median is 0.90 vs. the industry median of 0.28, Cresco Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cresco Labs's current Debt-to-Equity of 1.65 is 489.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current Debt-to-Equity is 1.65, which is 83% above median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.73, compared to a current price of €0.62 — trading 14.9% below its estimated fair value. The current Debt-to-Equity is 1.65, which is 83% above median its 10-year median of 0.90 and 489.3% above the Drug Manufacturers industry median of 0.28. Cresco Labs' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current Debt-to-Equity is 1.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cresco Labs (FRA:6CQ) Overvalued in 2026?
Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued.
The current stock price of €0.62 is trading 14.9% below its estimated GF Value™ of €0.73.
GuruFocus considers Cresco Labs to be Modestly Undervalued.
Key valuation signals for FRA:6CQ:
Debt-to-Equity: 1.65 (83% above median its 10-year median of 0.90)
GF Value™: €0.73 vs. price of €0.62 (14.9% below fair value)
Industry Position: 489.3% above the Drug Manufacturers median (#757 of 810)
No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
41GF Score
Get the complete analysis for FRA:6CQ
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6CQ has been successfully added to your 
